ARCTURUS THERAPEUTICS HOLDIN (ARCT) Stock Fundamental Analysis

NASDAQ:ARCT • US03969T1097

7.21 USD
+0.04 (+0.56%)
At close: Feb 13, 2026
7.21 USD
0 (0%)
After Hours: 2/13/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall ARCT gets a fundamental rating of 4 out of 10. We evaluated ARCT against 523 industry peers in the Biotechnology industry. While ARCT has a great health rating, there are worries on its profitability. ARCT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • ARCT had negative earnings in the past year.
  • ARCT had a negative operating cash flow in the past year.
  • ARCT had negative earnings in 4 of the past 5 years.
  • ARCT had negative operating cash flow in 4 of the past 5 years.
ARCT Yearly Net Income VS EBIT VS OCF VS FCFARCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

  • The Return On Assets of ARCT (-23.63%) is better than 73.04% of its industry peers.
  • ARCT has a better Return On Equity (-29.71%) than 76.48% of its industry peers.
Industry RankSector Rank
ROA -23.63%
ROE -29.71%
ROIC N/A
ROA(3y)-9.46%
ROA(5y)-19.07%
ROE(3y)-13.61%
ROE(5y)-29.65%
ROIC(3y)N/A
ROIC(5y)N/A
ARCT Yearly ROA, ROE, ROICARCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

  • ARCT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARCT Yearly Profit, Operating, Gross MarginsARCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • ARCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ARCT has more shares outstanding
  • The number of shares outstanding for ARCT has been increased compared to 5 years ago.
  • ARCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ARCT Yearly Shares OutstandingARCT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ARCT Yearly Total Debt VS Total AssetsARCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • ARCT has an Altman-Z score of 0.06. This is a bad value and indicates that ARCT is not financially healthy and even has some risk of bankruptcy.
  • ARCT's Altman-Z score of 0.06 is fine compared to the rest of the industry. ARCT outperforms 61.38% of its industry peers.
  • There is no outstanding debt for ARCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.06
ROIC/WACCN/A
WACC12.25%
ARCT Yearly LT Debt VS Equity VS FCFARCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 7.86 indicates that ARCT has no problem at all paying its short term obligations.
  • The Current ratio of ARCT (7.86) is better than 73.61% of its industry peers.
  • A Quick Ratio of 7.86 indicates that ARCT has no problem at all paying its short term obligations.
  • ARCT's Quick ratio of 7.86 is fine compared to the rest of the industry. ARCT outperforms 73.61% of its industry peers.
Industry RankSector Rank
Current Ratio 7.86
Quick Ratio 7.86
ARCT Yearly Current Assets VS Current LiabilitesARCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • ARCT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.81%.
  • ARCT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -39.15%.
  • The Revenue has been growing by 48.91% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-10.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.46%
Revenue 1Y (TTM)-39.15%
Revenue growth 3Y130.73%
Revenue growth 5Y48.91%
Sales Q2Q%-58.84%

3.2 Future

  • ARCT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.33% yearly.
  • ARCT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.00% yearly.
EPS Next Y30.07%
EPS Next 2Y-4.84%
EPS Next 3Y12.4%
EPS Next 5Y31.33%
Revenue Next Year-47.91%
Revenue Next 2Y-31.94%
Revenue Next 3Y-0.67%
Revenue Next 5Y24%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ARCT Yearly Revenue VS EstimatesARCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
ARCT Yearly EPS VS EstimatesARCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10 15

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ARCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ARCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARCT Price Earnings VS Forward Price EarningsARCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARCT Per share dataARCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • ARCT's earnings are expected to grow with 12.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.84%
EPS Next 3Y12.4%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ARCT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ARCTURUS THERAPEUTICS HOLDIN

NASDAQ:ARCT (2/13/2026, 8:00:00 PM)

After market: 7.21 0 (0%)

7.21

+0.04 (+0.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-02
Inst Owners66.1%
Inst Owner Change1.12%
Ins Owners0.6%
Ins Owner Change0%
Market Cap204.84M
Revenue(TTM)97.60M
Net Income(TTM)-66.71M
Analysts81.11
Price Target35.39 (390.85%)
Short Float %27.35%
Short Ratio11.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.14%
Min EPS beat(2)41.65%
Max EPS beat(2)62.62%
EPS beat(4)3
Avg EPS beat(4)16.94%
Min EPS beat(4)-98.22%
Max EPS beat(4)62.62%
EPS beat(8)7
Avg EPS beat(8)36.68%
EPS beat(12)10
Avg EPS beat(12)237.43%
EPS beat(16)13
Avg EPS beat(16)182.44%
Revenue beat(2)1
Avg Revenue beat(2)-0.15%
Min Revenue beat(2)-20.67%
Max Revenue beat(2)20.36%
Revenue beat(4)2
Avg Revenue beat(4)-10.16%
Min Revenue beat(4)-50.01%
Max Revenue beat(4)20.36%
Revenue beat(8)5
Avg Revenue beat(8)24.59%
Revenue beat(12)8
Avg Revenue beat(12)43.27%
Revenue beat(16)10
Avg Revenue beat(16)118.39%
PT rev (1m)8.02%
PT rev (3m)-22.51%
EPS NQ rev (1m)-6.27%
EPS NQ rev (3m)25.24%
EPS NY rev (1m)-2.01%
EPS NY rev (3m)21.79%
Revenue NQ rev (1m)-1.17%
Revenue NQ rev (3m)-8.13%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)-3.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.1
P/FCF N/A
P/OCF N/A
P/B 0.91
P/tB 0.91
EV/EBITDA N/A
EPS(TTM)-2.46
EYN/A
EPS(NY)-3.31
Fwd EYN/A
FCF(TTM)-2.06
FCFYN/A
OCF(TTM)-2.05
OCFYN/A
SpS3.44
BVpS7.9
TBVpS7.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -23.63%
ROE -29.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-9.46%
ROA(5y)-19.07%
ROE(3y)-13.61%
ROE(5y)-29.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.06%
Cap/Sales 0.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.86
Quick Ratio 7.86
Altman-Z 0.06
F-Score3
WACC12.25%
ROIC/WACCN/A
Cap/Depr(3y)207.21%
Cap/Depr(5y)221.18%
Cap/Sales(3y)1.97%
Cap/Sales(5y)10.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.46%
EPS Next Y30.07%
EPS Next 2Y-4.84%
EPS Next 3Y12.4%
EPS Next 5Y31.33%
Revenue 1Y (TTM)-39.15%
Revenue growth 3Y130.73%
Revenue growth 5Y48.91%
Sales Q2Q%-58.84%
Revenue Next Year-47.91%
Revenue Next 2Y-31.94%
Revenue Next 3Y-0.67%
Revenue Next 5Y24%
EBIT growth 1Y2.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.23%
EBIT Next 3Y-14.44%
EBIT Next 5YN/A
FCF growth 1Y-142.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-140.85%
OCF growth 3YN/A
OCF growth 5YN/A

ARCTURUS THERAPEUTICS HOLDIN / ARCT FAQ

Can you provide the ChartMill fundamental rating for ARCTURUS THERAPEUTICS HOLDIN?

ChartMill assigns a fundamental rating of 4 / 10 to ARCT.


What is the valuation status for ARCT stock?

ChartMill assigns a valuation rating of 0 / 10 to ARCTURUS THERAPEUTICS HOLDIN (ARCT). This can be considered as Overvalued.


What is the profitability of ARCT stock?

ARCTURUS THERAPEUTICS HOLDIN (ARCT) has a profitability rating of 1 / 10.